Lupin shares hit 52-week high after launch of HIV drug Darunavir in US

🔸Published: 05 Jun 2023 05:23 PM

🔸Updated: 10 Jun 2025 04:49 PM

After Lupin announced the release of its Darunavir Tablets as a generic alternative to Janssen Products' Prezista Tablets, its shares rose to a 52-week high of INR 830.3. According to IQVIA MAT March 2023, the US market for Darunavir Tablets is expected to generate revenues of about $308 million annually. Lupin also revealed that its stock price has increased by more than 16% in one month and more than 35% in one year. Additionally, the day RSI (14) of the company is at 79.8 and the MACD is at 24.7, both of which are bullish signals.

After the company announced the introduction of Darunavir Tablets, 600 mg, and 800 mg, to market a generic alternative to Prezista Tablets of Janssen Products, LP, shares of pharmaceutical giant Lupin increased by about 2% to reach a 52-week high of Rs 830.3 in Monday's trade on BSE.

According to IQVIA MAT March 2023, Lupin predicted that Darunavir Tablets, 600 mg and 800 mg (RLD Prezista) had US annual sales of $308 million.

Tablets containing darunavir are recommended for the treatment of HIV-1 infections. To help control HIV infection, the medicine is used along with other HIV medications. It helps to lower the body's level of HIV so that the immune system can function more effectively.

The stock went up 0.5% to Rs 821.3 at 11.30 am on the BSE. The stock has increased over 16% in the previous month and over 35% in the past year.

Lupin recorded a consolidated net profit of Rs 246.7 crore in Q4FY23, a decrease of 25.3% from the net profit of Rs 330.43 in the quarter ending in December 2022. EBITDA for the pharmaceutical company increased significantly, rising by an astounding 117.8% YoY to Rs 615 crore. Its operating revenue increased by 12% from Rs 3,864.50 crore in the same quarter a year before Rs 4,330.30 crore in Q4FY23.

According to Trendlyne statistics, the stock's average target price is down 11% from current market values at Rs 734. Lupin has received a Buy recommendation as a group from 36 analysts.

Technically, the day RSI (14) for the stock is at 79.8. According to data from Trendline, the RSI is oversold below 30 and overbought over 70. A bullish indicator, MACD is at 24.7, above its center and signal Line

Start Your Career Journey

Get hired in just one click